RxDoctor Payments Data

Zahid Zafar, MD

Internal Medicine · McKinney, TXNPI 1043209075

Payments from drug & device makers

$2,070,523in general payments, 2019–2025

Across 555 payments — averaging $3730.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$664K
  • Merck$622K
  • Genentech, Inc.$301K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$127K
  • Pfizer$124K
  • AstraZeneca$103K
  • plus $130K from 54 others
$218,191in research payments, 2019–2025

Across 3 payments — averaging $72,730 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$218K

What the payments were for

  • Food & beverage$6,08199%
  • Education$851%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly6$664,409
Merck47$621,782
Genentech, Inc.34$300,862
Otsuka Pharmaceutical Development & Commercialization, Inc.6$126,901
Pfizer35$123,722
AstraZeneca38$102,819
Esperion Therapeutics, Inc.70$45,012
Teva Pharmaceuticals USA, Inc.12$31,824
Sanofi US Services Inc.1$23,024
Vifor (international) Ltd.5$13,444
Chiesi USA, Inc.2$11,500
Amgen(2 entities)36$623
GSK34$536
Novartis24$421
Johnson & Johnson22$347
Sunovion Pharmaceuticals Inc.20$209
Sanofi-aventis U.S. LLC10$185
Otsuka America Pharmaceutical, Inc.10$184
Eisai Inc.8$170
Astellas Pharma US Inc6$163
Biogen9$159
Bayer7$145
AbbVie(2 entities)9$144
Abbott8$142
Acadia Pharmaceuticals Inc9$141
Sumitomo Pharma America, Inc.7$135
Inari Medical, Inc.5$133
Lilly USA, LLC7$119
Boehringer Ingelheim5$102
Endo Pharmaceuticals Inc.4$86
Corcept Therapeutics4$80
Exact Sciences4$67
Novo Nordisk4$67
Lundbeck LLC4$63
Phathom Pharmaceuticals, Inc.3$59
Vanda Pharmaceuticals Inc.2$55
Mylan Specialty L.p.3$47
Idorsia Pharmaceuticals US Inc2$46
Xeris Pharmaceuticals, Inc.2$42
Tanabe Pharma America, Inc.2$39
Biohaven Pharmaceutical Holding Company Ltd.2$38
Kvk-tech, Inc.1$37
Ironwood Pharmaceuticals, Inc2$36
Aimmune Therapeutics, Inc.2$35
Radius Health, Inc.2$31
Inspire Medical Systems, Inc.1$28
Globus Medical1$26
Amarin Pharma, Inc.2$26
Kyowa Kirin, Inc.1$24
Dexcom, Inc.1$24
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$21
Takeda Pharmaceuticals U.S.A., Inc.1$20
Medtronic1$19
Insulet Corporation1$19
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC1$16
Inogen, Inc.1$15
CMP Pharma, Inc.1$14
Tris Pharma Inc1$14
Stryker1$14
Boston Scientific1$14

How this compares

$2,070,523 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$439,079
Medicare patients
892
Services billed
4,421

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban392$240,472
OzempicSemaglutide168$187,634
JardianceEmpagliflozin112$124,717
JanuviaSitagliptin Phosphate68$71,665
MounjaroTirzepatide52$70,677
MyrbetriqMirabegron109$61,186
LinzessLinaclotide47$47,561
XifaxanRifaximin22$35,443
XareltoRivaroxaban45$34,206
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$32,008
FarxigaDapagliflozin Propanediol29$26,391
Tresiba Flextouch U-100Insulin Degludec35$25,103
ProliaDenosumab14$23,559
TrulicityDulaglutide13$23,145
NamzaricMemantine Hcl/Donepezil Hcl31$19,559

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$123,722$240,472392 claims
Novo NordiskOzempic$67$187,634168 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr$102$146,672149 claims
Lilly USA, LLCMounjaro, Trulicity$119$93,82365 claims
MerckJanuvia$621,782$71,66568 claims
AbbVieLinzess, Namzaric$144$67,12078 claims
Astellas Pharma US IncMyrbetriq$163$61,186109 claims
GSKTrelegy Ellipta, Anoro Ellipta$536$46,06549 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$16$35,44322 claims
Johnson & JohnsonXarelto$347$34,20645 claims
AstraZenecaFarxiga, Symbicort$102,819$33,87255 claims
AmgenProlia$623$23,55914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in McKinney

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →